Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 17, 2021 | Series Unknown | $60M | 1 | — | — | Detail |
| Feb 2, 2021 | Series A | — | 2 | — | — | Detail |
| Dec 20, 2019 | Series Unknown | $750K | 1 | — | — | Detail |
| Sep 6, 2017 | Seed | $10M | 1 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Norwest Venture Partners
|
— | Series Unknown |
ARCH Venture Partners
|
— | Series A |
Gaingels
|
— | Series Unknown |